Form 4: Haemonetics Corp Executive Roy Galvin Reports Acquisition of Shares and Stock Options

Roy Galvin, President of Global Plasma & BC at Haemonetics Corp, reports the acquisition of common stock and stock options.

Summary

• Roy Galvin, President, Global Plasma & BC of Haemonetics Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 17, 2024, Galvin acquired 2,872 shares of common stock in the form of restricted stock units (RSUs).
• Galvin also acquired options to purchase 6,313 shares of common stock at an exercise price of $95.73, vesting in annual increments of 25% beginning on the first anniversary of the grant date.
• Following these transactions, Galvin beneficially owns 7,410 shares of common stock, including unvested RSUs previously reported, and options for 6,313 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard regulatory filing. The acquisition of shares and options by an executive could be interpreted as a slightly positive signal, but it's not a strong indicator.

Positives

• The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions reported may have a minor positive impact on shareholder sentiment, as insider ownership is often viewed favorably.

Key Dates